A Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus

Idiopathic Normal Pressure Hydrocephalus Clinical Trial

Official title:

A Randomized Trial of High and Low Pressure Level Settings on a Programmable Ventriculoperitoneal Shunt Valve for Idiopathic Normal Pressure Hydrocephalus. Results of the Dutch Evaluation Program Strata Shunt (DEPSS) Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01570257
• Other study ID #: MEC 03.1073
• Status: Completed
• Phase: N/A
• First received: March 25, 2012
• Last updated: August 2, 2016
• Start date: September 2003
• Est. completion date: October 2007

Study information

• Verified date: March 2012
• Source: Erasmus Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)
• Study type: Interventional

Clinical Trial Summary

In treating idiopathic normal pressure hydrocephalus with a shunt there is always a risk of underdrainage or overdrainage. The hypothesis is tested whether treatment of patients with an adjustable valve preset at the highest opening pressure (OPV), leads to comparable clinical results with less subdural effusions than in a control group with an opening pressure preset and kept fixed at a low pressure level.

Description:

Idiopathic normal pressure hydrocephalus (INPH) is characterized by a clinical triad of symptoms: gait disturbance, urinary incontinence and cognitive impairment. INPH typically develops among the elderly and shares some symptoms with other neurological disorders. In general, 60-70% of patients with the complete clinical triad and signs of hydrocephalus on CT/MRI will improve after cerebrospinal fluid (CSF) shunting. Implantation of a shunt, however, carries complications such as infection, obstruction, underdrainage, and overdrainage. The cumulative complication rate and revision rate is estimated to be 35-80% among adults. The England shunt registry described an overall incidence of underdrainage of 52%, and studies have resulted in incidences of overdrainage between 2 and 21%. Børgesen claims that 80% of complications of shunting for INPH are related to overdrainage. Overdrainage may lead to low intracranial pressure syndrome and subdural effusions (SDE). Low intracranial pressure syndrome is characterized by orthostatic headaches and sometimes nausea, vomiting, drowsiness, diplopia, upward gaze palsy and visual defects. As INPH patients are often elderly patients with concomitant brain atrophy and normal CSF pressure they are especially at risk for developing signs and symptoms of overdrainage.

Overdrainage can be prevented or treated by implanting an anti-siphon device (ASD) or changing the opening pressure of the valve (OPV). Different ASDs have been developed since the first publication in 1973. They have in common that the lumen of the catheter is closed under influence of a negative hydrostatic pressure at the level of the ASD. The optimal valve setting for treating INPH is still the subject of controversy. The dilemma in INPH patients is that a low OPV might lead to overdrainage-related symptoms. A high valve setting might lead to underdrainage and the patient misses the chance of maximum improvement.

Studies examining whether to use a low or high OPV have been contradictory so far.

After randomization, baseline primary and secondary outcome measure assessments are conducted preoperatively. Within 24 hours of shunting, skull, thoracic, and abdominal X-rays are done to verify device connections and position. Follow-up visits at 1, 3, and 9 months include all primary and secondary outcome assessments. All measurements are done by a research assistant who visits the participating hospitals to prevent inter-observer variation. Study end for each patient is defined as completing the 9 month visit or death, detection of SDE on CT, or shunt removal or revision due to infection or dysfunction.

The PL in Group 1 (control group) is allowed to be increased to a higher setting when an SDE is detected. The patient thereby reaches study end, and the treating physician is free to decide how to manage the PL. The 9-month follow-up is still obtained. The PL in Group 2 is preset at the highest PL and eventually lowered 1 step at each follow-up visit when the modified mini mental state (3MS) or Gait score is not increased ≥ 15% provided that no SDE is visible on a new CT scan. The 15% is considered the minimum percentage to reliably determine improvement.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: October 2007
• Est. primary completion date: December 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 85 Years

Eligibility

Inclusion Criteria:

• At least two out of three of the typical signs of normal pressure hydrocephalus:

• gait disturbance,

• cognitive impairment and

• urinary incontinence.

• Radiological verification of a communicating hydrocephalus.

• Cerebrospinal fluid pressure at lumbar puncture < 150 mm H2O.

Exclusion Criteria:

• Aqueduct stenosis.

• Severe comorbidity.

• Age > 85 years.

• Possibly confounding neurological diseases.

• Recent meningitis or subarachnoid hemorrhage.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hydrocephalus
• Hydrocephalus, Normal Pressure
• Idiopathic Normal Pressure Hydrocephalus

Intervention

Procedure:
• lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus
in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.

Locations

Country	Name	City	State
Netherlands	Erasmus Medical Center	Rotterdam	Zuid Holland

Sponsors (8)

Lead Sponsor	Collaborator
Erasmus Medical Center	Admiraal de Ruyter Hospital, Goes, the Netherlands, Albert Schweitzer Hospital, Atrium Medical Center, Isala, Medtronic, UMC Utrecht, University Medical Center Nijmegen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the number of Subdural effusions, detected on CT scan, in patients showing clinical improvement after implantation of a ventriculoperitoneal shunt,at the end of the study	the most important parameter of the study will be the difference in incidence of subdural effusions between both groups	baseline and 9 months (end of study)	No
Secondary	the final performance level of the valve of the shunt at the end of the study	Peformance level is the opening/closing pressure of the valve and reflects the hydrostatic resistance of the valve of the shunt	baseline and 9 months (end of study)	No
Secondary	change in gait score		baseline and 9 months (end of study)	No
Secondary	change in urinary incontinence		baseline and 9 months (end of study)	No
Secondary	change in modified mini mental state (3MS) score	the 3MS score quantifies cognitive function	baseline and 9 months (end of study)	No
Secondary	change in modified Rankin (mRS) score	the mRS quantifies functional impairment	baseline and 9 months (end of study)	No
Secondary	change in Evans' ratio	a measure of ventricular width, on CT scan	baseline and 9 months (end of study)	No